Provided is an afucosylated monoclonal antibody. The monoclonal antibody is a human IgG antibody and has an afucosylated sugar chain structure at a heavy-chain sugar chain binding site. Also provided are application of the monoclonal antibody in the preparation of antineoplastic drugs, and a ...
7. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994 Oct 15;84(8):2457-66....
Enhancement of antibody-dependent cellular cytotoxicity (ADCC) is a promising adjunct approach to achieve HIV control in the absence of antiretroviral therapy but requires the development of potent ADCC-eliciting antibodies which can recognise diverse HIV-infected cell types. A panel of broadly ...
AFUCOSYLATED MONOCLONAL ANTIBODY 专利名称：AFUCOSYLATED MONOCLONAL ANTIBODY 发明人：Bo Tang,Ran Zhang,Jianmin Zhao,Jianwu Wang,Yunping Dai 申请号：US16345648 申请日：20170724 公开号：US20200270358A1 公开日：20200827 专利内容由知识产权出版社提供 摘要：Provided is an afucosylated monoclonal antibody. The ...
Provided is an afucosylated monoclonal antibody. The monoclonal antibody is a human IgG antibody and has an afucosylated sugar chain structure at a heavy-chain sugar chain binding site. Also provided are application of the monoclonal antibody in the preparation of antineoplastic drugs, and a compositi...
[0032] 术语“CCR5”表示人趋化因子受体(见例如Swiss Prot P51681和Mueller,Α., 和 Strange, P. G.,Int. J. Biochem. Cell Biol. 36(2004)35-38)。术语 “CCR5 抗体”意为抗 CCR5 的抗体(antibody against CCR5),抗 CCR5 抗体(anti_CCR5antibody)。
Long-term Prophylaxis Against Aerosolized Marburg Virus in Nonhuman Primates With an Afucosylated Monoclonal Antibody Abelson, Dafna,Barajas, Jennifer,Stuart, Lauren,... - 《Journal of Infectious Diseases》 - 2023 - 被引量: 0 Therapeutic afucosylated mon...
https://doi.org/10.1016/S0022-3565(24)46040-0Get rights and contentAccess through your organization Check access to the full text by signing in through your organization. Access through your organization References (0) Cited by (0)View full text ...
2.Shields, R.L., et al., Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem, 2002. 277(30): p. 26733-40. 3.Kanda, Y., et al., Comparison of biological activity among nonfucosylated thera...
FIELD: medicine, pharmacy.;SUBSTANCE: invention refers to biotechnology, specifically to combination therapy by afucosylated antibody for CD20 and antibody for VEGF for cancer treatment, which can be used in medicine. A afucosylated humanized B-Ly1 antibody is applied in combination with the antibody ...